Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: Effect of acquired immunity

Journal of Infectious Diseases

Volumn 207, Issue 11, 2013, Pages 1655-1663

  Lopera Mesa, Tatiana M ^a   Doumbia, Saibou ^b   Chiang, Serena ^a   Zeituni, Amir E ^a   Konate, Drissa S ^b   Doumbouya, Mory ^b   Keita, Abdoul S ^b   Stepniewska, Kasia ^c   Traore, Karim ^b   Diakite, Seidina A S ^b   Ndiaye, Daouda ^d   Sa, Juliana M ^a   Anderson, Jennifer M ^a   Fay, Michael P ^a   Long, Carole A ^a   Diakite, Mahamadou ^b   Fairhurst, Rick M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF BAMAKO   (Mali)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

Author keywords

antimalarial immunity; artemisinin; malaria; Mali; parasite clearance; Plasmodium falciparum

Indexed keywords

AMODIAQUINE; ARTEMISININ DERIVATIVE; ARTESUNATE; CHLOROQUINE; DEETHYLAMODIAQUINE; IMMUNOGLOBULIN G; QUININE;

ADAPTIVE IMMUNITY; ADOLESCENT; AGE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CHILD; CONTROLLED STUDY; ERYTHROCYTE; ETHNIC DIFFERENCE; ETHNIC GROUP; ETHNICITY; EX VIVO STUDY; FEMALE; GENETIC POLYMORPHISM; GEOMETRY; HALF LIFE TIME; HUMAN; IC 50; IMMUNOREACTIVITY; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MALIAN; NONHUMAN; PATHOGEN CLEARANCE; PLASMODIUM FALCIPARUM; POPULATION DENSITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEX; SOUTHEAST ASIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADAPTIVE IMMUNITY; ADOLESCENT; AMODIAQUINE; ANTIBODIES, PROTOZOAN; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ERYTHROCYTES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; MALARIA, FALCIPARUM; MALE; MALI; PARASITE LOAD; PARASITEMIA; PLASMODIUM FALCIPARUM;

EID: 84877259000     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit082     Document Type: Article

References (43)

1. Jiang JB, Li GQ, Guo XB, Kong YC, Arnold K. Antimalarial activity of mefloquine and qinghaosu. Lancet 1982; 2:285-8.
2. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366:717-25.
3. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376:1647-57.
4. World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva, Switzerland:World Health Organization, 2010.
5. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 2007; 77:181-92.
6. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol 2009; 7:864-74.
7. World Health Organization. Global report on antimalarial efficacy and drug resistance: 2000-2010. Geneva, Switzerland: World Health Organization, 2010.
8. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-67.
9. Amaratunga C, Sreng S, Suon S, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 2012; 12:851-8.
10. Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisininresistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012; 379:1960-6.
11. Toshihiro M, Venkatesan M, Ohashi J, et al. Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations. J Infect Dis 2011; 204:1980-8.
12. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004; 305:1124.
13. Ariey F, Fandeur T, Durand R, et al. Invasion of Africa by a single pfcrt allele of South East Asian type. Malar J 2006; 5:34.
14. Fairhurst RM, Nayyar GM, Breman JG, et al. Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am J Trop Med Hyg 2012; 87:231-41.
15. Lim P, Alker AP, Khim N, et al. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J 2009; 8:11.
16. Anderson TJ, Nair S, Nkhoma S, et al. High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J Infect Dis 2010; 201:1326-30.
17. Cheeseman IH, Miller BA, Nair S, et al. A major genome region underlying artemisinin resistance in malaria. Science 2012; 336:79-82.
18. Stepniewska K, Ashley E, Lee SJ, et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 2010; 201:570-9.
19. Maiga AW, Fofana B, Sagara I, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg 2012; 87:23-8.
20. Newton PN, Green MD, Mildenhall DC, et al. Poor quality vital antimalarials in Africa-an urgent neglected public health priority. Malar J 2011; 10:352.
21. O'Neill PM, Barton VE, Ward SA. The molecular mechanism of action of artemisinin-the debate continues. Molecules 2010; 15:1705-21.
22. Chotivanich K, Udomsangpetch R, Dondorp A, et al. The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis 2000; 182:629-33.
23. Newton PN, Chotivanich K, ChierakulW, et al. A comparison of the in vivo kinetics of Plasmodium falciparum ring-infected erythrocyte surface antigen-positive and-negative erythrocytes. Blood 2001; 98:450-7.
24. Chotivanich K, Udomsangpetch R, McGready R, et al. Central role of the spleen in malaria parasite clearance. J Infect Dis 2002; 185:1538-41.
25. Buffet PA, Milon G, Brousse V, et al. Ex vivo perfusion of human spleens maintains clearing and processing functions. Blood 2006; 107:3745-52.
26. Beaudry JT, Fairhurst RM. Microvascular sequestration of Plasmodium falciparum. Blood 2011; 117:6410.
27. Guindo A, Fairhurst RM, Doumbo OK, Wellems TE, Diallo DA. Xlinked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med 2007; 4:e66.
28. Crompton PD, Traore B, Kayentao K, et al. Sickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria. J Infect Dis 2008; 198:1265-75.
29. White NJ. The parasite clearance curve. Malar J 2011; 10:278.
30. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J 2011; 10:339.
31. Ndiaye D, Patel V, Demas A, et al. A non-radioactive DAPI-based high-throughput in vitro assay to assess Plasmodium falciparum responsiveness to antimalarials-increased sensitivity of P. falciparum to chloroquine in Senegal. Am J Trop Med Hyg 2010; 82:228-30.
32. Wellems TE, Panton LJ, Gluzman IY, et al. Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross. Nature 1990; 345:253-5.
33. Walliker D, Quakyi IA, Wellems TE, et al. Genetic analysis of the human malaria parasite Plasmodium falciparum. Science 1987; 236: 1661-6.
34. Silamut K, Phu NH, Whitty C, et al. A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Pathol 1999; 155:395-410.
35. Modiano D, Petrarca V, Sirima BS, et al. Different response to Plasmodium falciparum malaria in west African sympatric ethnic groups. Proc Natl Acad Sci USA 1996; 93:13206-11.
36. Kaddouri H, Djimde A, Dama S, et al. Baseline in vitro efficacy of ACT component drugs on Plasmodium falciparum clinical isolates from Mali. Int J Parasitol 2008; 38:791-8.
37. Staalsoe T, Giha HA, Dodoo D, Theander TG, Hviid L. Detection of antibodies to variant antigens on Plasmodium falciparum-infected erythrocytes by flow cytometry. Cytometry 1999; 35:329-36.
38. Warimwe GM, Keane TM, Fegan G, et al. Plasmodium falciparum var gene expression is modified by host immunity. Proc Natl Acad Sci USA 2009; 106:21801-6.
39. Diatta AM, Marrama L, Tall A, et al. Relationship of binding of immunoglobulin G to Plasmodium falciparum-infected erythrocytes with parasite endemicity and antibody responses to conserved antigen in immune individuals. Clin Diagn Lab Immunol 2004; 11:6-11.
40. Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med 1998; 4:358-60.
41. Mackintosh CL, Mwangi T, Kinyanjui SM, et al. Failure to respond to the surface of Plasmodium falciparum-infected erythrocytes predicts susceptibility to clinical malaria amongst African children. Int J Parasitol 2008; 38:1445-54.
42. Djimde AA, Doumbo OK, Traore O, et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 2003; 69:558-63.
43. Cohen S, Mc GI, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961; 192:733-7.